CytomX Therapeutics (CTMX) CEO receives 980,000 options and RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CytomX Therapeutics CEO Sean A. McCarthy reported new equity awards. On February 2, 2026, he was granted stock options for 980,000 shares of Common Stock with a $6.09 exercise price, vesting in equal monthly installments over four years from that date and expiring on February 1, 2036.
He also acquired 210,000 shares of Common Stock at $0 as restricted stock units, which vest in three equal annual installments each March 15, starting March 15, 2027, contingent on continued service. After these grants, he beneficially owns 1,197,891 shares directly, including 698,750 RSUs, plus 93,158 shares held indirectly by the Sean A. McCarthy 2018 Trust, for which he serves as trustee.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
McCarthy Sean A.
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 980,000 | $0.00 | -- |
| Grant/Award | Common Stock | 210,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 980,000 shares (Direct);
Common Stock — 1,197,891 shares (Direct);
Common Stock — 93,158 shares (Indirect, See footnote)
Footnotes (1)
- Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 698,750 RSUs. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Shares held by Sean A. McCarthy 2018 Trust, of which the Reporting Person is trustee.
FAQ
What equity awards did CytomX (CTMX) CEO Sean A. McCarthy receive?
Sean A. McCarthy received stock options for 980,000 shares and 210,000 restricted stock units. The options have a $6.09 exercise price, while the RSUs convert into one share of Common Stock each upon vesting, providing long-term, service-based compensation.
What are the vesting terms of the new CytomX (CTMX) stock options?
The 980,000 stock options vest in 48 equal monthly installments from February 2, 2026. All options are scheduled to be fully vested and exercisable on the fourth anniversary of that date, assuming Sean A. McCarthy continues to provide service to CytomX throughout the vesting period.
How do the CytomX (CTMX) CEO’s RSUs vest over time?
The 210,000 RSUs vest in three equal annual installments on March 15 each year. The first one-third is scheduled to vest on March 15, 2027, with additional vesting conditioned on Sean A. McCarthy’s continued service as a provider to CytomX on each vesting date.
What is the exercise price and expiration date of the new CytomX (CTMX) stock options?
The newly granted stock options have a $6.09 exercise price per share and an expiration date of February 1, 2036. These options only become exercisable as they vest over the four-year schedule tied to Sean A. McCarthy’s continued service with CytomX.